EBITDA: Income before interest, taxes, depreciation and amortization.
Metagenomi Therapeutics, Inc. (MGX) had EBITDA of $-27.07M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$-0.26M |
|
$-27.48M |
|
-- |
|
$-0.26M |
|
$28.52M |
|
$-28.77M |
|
$1.29M |
|
$-27.48M |
|
$-27.48M |
|
$-27.48M |
|
$-27.48M |
|
$-27.48M |
|
$-27.48M |
|
$-28.77M |
|
|
EBITDA |
$-27.07M |
37.66M |
|
37.66M |
|
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$124.47M |
|
$9.90M |
|
$49.23M |
|
$173.70M |
|
$27.63M |
|
-- |
|
$33.50M |
|
$61.13M |
|
$112.57M |
|
$112.57M |
|
$112.57M |
|
37.78M |
|
| Cash Flow Statement Financials | |
$-40.69M |
|
$37.15M |
|
$0.04M |
|
$46.91M |
|
$43.42M |
|
$-3.49M |
|
$4.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
11195.72% |
|
11195.72% |
|
-- |
|
10693.39% |
|
10693.39% |
|
$-40.84M |
|
-- |
|
-- |
|
-- |
|
-0.00 |
|
-- |
|
-- |
|
-- |
|
-24.41% |
|
-24.41% |
|
-15.82% |
|
-24.41% |
|
$2.98 |
|
$-1.08 |
|
$-1.08 |
|